Notice: Survey on the Impact of the 2024 Medical Fee Revision on Medical Corporations – M&A Capital Partners

News Highlights

M&A Capital Partners has announced the results of a survey on the impact of the FY2024 medical fee revision on the management of medical corporations. Key discussion points for medical M&A and business succession include early response to the revision, maintaining facility standards and dispersing equipment investment burdens through economies of scale, and utilizing tax preferential treatment by transitioning to specific or social medical corporations. The necessity of mid-to-long-term management and succession strategies is suggested.

Perspective from the M&A Medical Editorial Department

The FY2024 medical fee revision is an urgent issue directly linked to the sustainable management of medical corporations. As M&A Capital Partners points out, the integration of mid-to-long-term strategies and business succession strategies, considering the revision cycle, is unavoidable. For example, participation in regional medical cooperation promotion corporations or maintaining large-scale facility standards and dispersing equipment investment burdens through group formation can be management improvement measures that are difficult to achieve individually. Furthermore, utilizing tax schemes with a view to transitioning to specific or social medical corporations can be an incentive for M&A involving changes in corporate status. Many medical corporations are now required to consider business succession and M&A not merely as cost reduction measures, but as integrated with the restructuring of their revenue base.

Discussion Points Indicated by This News

• The FY2024 medical fee revision directly impacts the revenue structure of medical corporations, prompting a review of business succession strategies.
• Economies of scale through group formation contribute to solving specific management challenges such as maintaining facility standards and dispersing equipment investment burdens.
• Utilizing tax schemes with a view to transitioning to specific or social medical corporations can be a significant incentive in M&A.
• The necessity of predicting the revision cycle and aligning mid-to-long-term management strategies with business succession strategies is increasing.

Practical Questions Arising from This News

• Which specific medical departments or services will be affected by this revision?
• To what extent will facility standard maintenance and equipment investment burdens be reduced through group formation?
• What are the procedures, merits, and demerits of transitioning to specific or social medical corporations?

If You Feel “Should I Consult Too?”

If you are struggling to grasp the specific impact of the FY2024 medical fee revision and how to integrate it into your institution’s management and succession strategies, you should consider consulting with experts. In particular, receiving specific simulations regarding the possibility of M&A involving changes in corporate status, such as enjoying economies of scale through group formation or utilizing tax preferential treatment as a measure against revenue reduction risk due to the revision, will serve as a basis for decision-making.

M&A Medical (CentralMedience Inc.) supports the business succession of medical corporations, hospitals, and clinics on a full success fee basis as an M&A support institution certified by the Small and Medium Enterprise Agency. Consultations are accepted with strict confidentiality. Free consultation here